Cargando…

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()

AIM: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. METHODS: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aomar-Millán, Ismael Francisco, Salvatierra, Juan, Torres-Parejo, Úrsula, Nuñez-Nuñez, María, Hernández-Quero, José, Anguita-Santos, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142037/ https://www.ncbi.nlm.nih.gov/pubmed/34056111 http://dx.doi.org/10.1016/j.medcle.2021.01.004

Ejemplares similares

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study
por: Dolci, Giovanni, et al.
Publicado: (2021)

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
por: Jiménez-Brítez, Gustavo, et al.
Publicado: (2020)

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
por: Jiménez-Brítez, Gustavo, et al.
Publicado: (2020)

Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
por: Mori, Shunsuke, et al.
Publicado: (2014)

Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone
por: Belhassen-García, Moncef, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report
por: Cai, Sisi, et al.
Publicado: (2019)

Successful treatment of granulomatosis with polyangiitis using tocilizumab combined with glucocorticoids: A case report
por: Tang, Peng-Fang, et al.
Publicado: (2023)

Aetiology and prognostic risk factors of mortality in patients with pneumonia receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study
por: Li, Lijuan, et al.
Publicado: (2020)

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022)

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022)

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
por: Camou, Fabrice, et al.
Publicado: (2022)

An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy
por: Sakashita, Kentaro, et al.
Publicado: (2016)

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

Glucocorticoids/siltuximab/tocilizumab: Hepatitis-B reactivation following off-label use: 2 case reports
Publicado: (2021)

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis
por: Zeraatkar, Dena, et al.
Publicado: (2022)

Dexametasona frente a metilprednisolona ajustada al peso en pacientes con neumonía moderada-grave por SARS-CoV-2
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis
por: Du, Wen, et al.
Publicado: (2023)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Tocilizumab: Secondary organising pneumonia: case report
Publicado: (2022)

Treatment of Glucocorticoid-Induced Osteoporosis with Bisphosphonates Alone, Vitamin D Alone or a Combination Treatment in Eastern Asians: A Meta-Analysis
por: Wang, Junjie, et al.
Publicado: (2019)

Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial)
por: Christ, Lisa, et al.
Publicado: (2023)

A Fatal Case of Concurrent Disseminated Tuberculosis, Pneumocystis Pneumonia, and Bacterial Septic Shock in a Patient with Rheumatoid Arthritis Receiving Methotrexate, Glucocorticoid, and Tocilizumab: An Autopsy Report
por: Ohmura, Shin-Ichiro, et al.
Publicado: (2021)

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)
por: Kaneko, Yuko, et al.
Publicado: (2018)

A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital
por: AlBahrani, Salma, et al.
Publicado: (2021)

Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study
por: Mussini, Cristina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1evmjfh8uh9j5dktjibgr7op9